No takes yet. Share an insight, caveat, or question.
Randomized trial explores allogeneic HSCT outcomes in patients with inborn errors of immunity, highlighting key strategies for improved survival.
Katsutsugu Umeda (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: